ABOS: Phase II data for a novel Alzheimer's antibody is expected in Q4 2024, with EBD IND in 2027
Sabirnetug, a selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected in late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027. Key milestones include robust clinical retention and advancing two EBD candidates.Ba…